Compare CRC & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | LGND |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | CRC | LGND |
|---|---|---|
| Price | $60.16 | $204.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $61.88 | ★ $245.17 |
| AVG Volume (30 Days) | ★ 650.5K | 144.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.08 |
| Revenue Next Year | $3.53 | $17.83 |
| P/E Ratio | ★ $13.50 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.69 | $93.58 |
| 52 Week High | $62.48 | $212.49 |
| Indicator | CRC | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 64.18 |
| Support Level | $45.54 | $198.52 |
| Resistance Level | N/A | $207.72 |
| Average True Range (ATR) | 2.09 | 7.80 |
| MACD | 0.00 | 2.19 |
| Stochastic Oscillator | 70.41 | 93.00 |
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.